Tavegil 1 mg tablets, No. 20
Ingredients
Active ingredient: clemastine;
1 tablet contains 1.34 mg of clemastine fumarate, equivalent to 1 mg of clemastine;
inactive ingredients: magnesium stearate, povidone, talc, corn starch, lactose monohydrate.
Dosage Form
Tablets.
Main physical and chemical properties: white or almost white, round, flat tablets with beveled edges. One side is scored and engraved with “O/T.”
Pharmacotherapeutic group
Antihistamines for systemic use.
ATC code R06A A04.
Pharmacological properties
Pharmacodynamics.
Tavegil is an H1-receptor antagonist. It belongs to the benzhydryl ester class of antihistamines. Tavegil selectively inhibits histamine H1 receptors and reduces capillary permeability. It exerts a pronounced antihistamine and antipruritic effect, characterized by a rapid onset and significant duration (up to 12 hours).
Pharmacokinetics.
After oral administration, clemastine is almost completely absorbed from the gastrointestinal tract. Maximum plasma concentration is reached in 2–5 hours. The peak antihistamine effect of the drug is observed after 5–7 hours and lasts for 10–12 hours, sometimes up to 24 hours. The plasma protein binding of clemastine is approximately 95%.
Elimination from plasma is biphasic, with half-lives of 3.6 ± 0.9 hours and 37 ± 16 hours, respectively. Clemastine is extensively metabolized in the liver. The primary route of metabolite excretion is via urine (45–65%). Only small amounts of the unchanged active ingredient are detected in urine. The drug is excreted into breast milk in significant amounts.
Indications
Hay fever, allergic rhinitis, urticaria (including dermographic urticaria), pruritus, allergic dermatoses; as an adjunctive treatment for acute and chronic eczema; contact dermatitis, as well as allergic reactions caused by medications or insect bites.
Contraindications
Hypersensitivity to clemastine or to the excipients of the drug, as well as to antihistamines with a similar chemical structure; porphyria.
Interactions with Other Medications and Other Types of Interactions
Tavegil, like other antihistamines, potentiates the sedative effects of drugs that depress the central nervous system (hypnotics, MAO inhibitors, tricyclic antidepressants, anxiolytics, opioid analgesics, and alcohol). Clemastine may enhance the effects of certain anticholinergic agents (e.g., atropine, tricyclic antidepressants). Alcohol consumption should be avoided while taking this medication.
Special Considerations for Use
Tavegil tablets contain lactose. Patients with hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medication.
Tavegil should be used with caution in patients with a history of epilepsy or seizures, angle-closure glaucoma, peptic gastric ulcer with stenosis, pyloroduodenal stenosis, prostatic hypertrophy with urinary retention, and bladder neck obstruction. Use with caution in elderly patients, who are at higher risk for adverse reactions such as paradoxical excitement; avoid use in cases of confusion.
Use during pregnancy or breastfeeding.
Tavegil should not be prescribed during pregnancy or while breastfeeding. Antihistamines may pass into breast milk and affect the newborn.
Effect on reaction time when driving or operating machinery.
Due to the sedative effect of clemastine, this medication may impair the ability to drive or operate machinery.
Dosage and Administration
Take the tablets before meals with water.
Adults and children 12 years of age and older should take 1 tablet in the morning and 1 tablet in the evening. In particularly severe cases, the daily dose may be increased to 6 tablets; the maximum single dose is 2 tablets.
Children aged 6 to 12 years should take ½ to 1 tablet before breakfast and at bedtime.
Do not use this medication for more than 14 days without consulting a doctor. Do not exceed the recommended dose. For oral use only.
Children.
In this dosage form, the medication is indicated for children aged 6 years and older.
Overdose
An overdose of antihistamines may result in either depression or excitation of the central nervous system (impaired consciousness, agitation, hallucinations, seizures). Anticholinergic symptoms may also occur (dry mouth, mydriasis, flushing, gastrointestinal disturbances, and tachycardia).
Treatment consists of removing the drug from the body by gastric lavage, administering adsorbents, and providing symptomatic therapy.
Side Effects
The side effects listed below may occur with the following frequency: very common (≥ 1/10), common (≥ 1/100, < 1/10), uncommon (≥ 1/1,000, < 1/100), rarely (≥1/10,000, < 1/1,000), very rarely (< 1/10,000).
Nervous system: common—increased fatigue, sedative effects, drowsiness; uncommon—dizziness; rare—headache.
Psychiatric disorders: rare – agitation (especially in children).
Gastrointestinal system: rare—gastrointestinal disorders, including epigastric pain, nausea, dry mouth; very rare—constipation.
Cardiovascular system: very rarely—tachycardia, palpitations.
Skin: rare – skin rashes.
Immune system disorders: rare—hypersensitivity reactions, shortness of breath; isolated cases—anaphylactic shock.
General disorders: rarely—asthenia.
Shelf life
3 years.
Storage conditions
Store out of the reach of children at a temperature not exceeding 30 °C.
Packaging
20 tablets per blister pack; 1 blister pack per cardboard box.
Dispensing Category
Available without a prescription.
Manufacturer
SmithKline Beecham S.A.
Manufacturer’s location and address of its place of business.
Ctra. de Ajalvir, Km 2.500, Alcalá de Henares 28806 (Madrid), Spain
Similar products
Products from the same category











